{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:00:08Z","timestamp":1790791208497,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005129D122"],"award-info":[{"award-number":["005129D122"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RAMOS23A0"],"award-info":[{"award-number":["RAMOS23A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000056","name":"NINR","doi-asserted-by":"publisher","award":["R01 NR020470"],"award-info":[{"award-number":["R01 NR020470"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","award":["R01 FD006848"],"award-info":[{"award-number":["R01 FD006848"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Black and Hispanic people with cystic fibrosis (PwCF) experience worse health outcomes related to pulmonary disease compared with White, non-Hispanic PwCF. Improving outcomes in minoritized PwCF is a crucial need in the CF community, but prior evidence suggests that these communities are underrepresented in CF clinical research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether CF clinical studies are representative of the overall CF population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study cohort included participants from recent CF transmembrane conductance regulator modulator studies: Characterizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (CHEC-SC), A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (PROMISE), Prospective Longitudinal Study of CFTR-dependent Disease Profiling in CF (PROSPECT), and the G551D Observational Study. Persons seen at the same centers who were eligible for these studies based on the inclusion and exclusion criteria but did not enroll were used as a comparator cohort from the Cystic Fibrosis Foundation Patient Registry (CFFPR). Rates of study enrollment were assessed separately for Black race and Hispanic ethnicity versus non-Hispanic White PwCF. Propensity-weighted Poisson regression models were used to account for potential confounders in the relationship between race and study participation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Demographic characteristics were compared between 3594 PwCF in the 4 modulator studies with 14\u200a888 individuals from the CFFPR who were eligible but did not enroll. Enrollees were younger (median age 19\u2009years), more likely to have had at least 3 clinic visits per year, and more likely to live within 30 miles of the study site. Black and Hispanic PwCF were less likely to have private insurance and less likely to live far from study centers. Multivariable analysis revealed that Black individuals were significantly less likely than non-Hispanic White individuals to enroll in CHEC-SC and PROMISE, with a 17% and 32% lower likelihood, respectively. Hispanic individuals had a 34% lower enrollment rate than non-Hispanic White individuals in PROMISE but had a higher enrollment in PROSPECT. Differences in enrollment rates were greater at sites with fewer minority participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results suggest that Black and Hispanic PwCF are, overall, significantly less likely to be included in CF clinical research than non-Hispanic White PwCF. Future research is needed to better understand if these differences are upheld in studies with varying inclusion\/exclusion criteria and clinical sites.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/annalsats\/aaoag085","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:05:57Z","timestamp":1776135957000},"page":"1446-1454","source":"Crossref","is-referenced-by-count":0,"title":["Representation of minoritized people with cystic fibrosis in the Cystic Fibrosis Therapeutics Development Network clinical trials"],"prefix":"10.1093","volume":"23","author":[{"given":"Tijana","family":"Milinic","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia S","family":"Magaret","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Pediatrics, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1223-7422","authenticated-orcid":false,"given":"Crystal E","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Department of Bioethics and Humanities, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J","family":"McElvaney","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Pediatrics, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Department of Pediatrics, Seattle Children\u2019s Research Institute , Seattle, WA,","place":["United States"]},{"name":"Department of Biostatistics, School of Public Health, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha G","family":"Kapnadak","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7100-512X","authenticated-orcid":false,"given":"Susan R","family":"Heckbert","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen J","family":"Ramos","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Department of Pediatrics, Seattle Children\u2019s Research Institute , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Goss","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Division of Pulmonary Medicine, Department of Pediatrics, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Department of Pediatrics, Seattle Children\u2019s Research Institute , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"2026093013524326700_aaoag085-B1","volume-title":"Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report","author":"Cystic Fibrosis Foundation","year":"2022"},{"key":"2026093013524326700_aaoag085-B2","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"2026093013524326700_aaoag085-B3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jcf.2021.03.027","article-title":"Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?","volume":"20","author":"Dobra","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026093013524326700_aaoag085-B4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1164\/rccm.200502-273OC","article-title":"Clinical trial participants compared with nonparticipants in cystic fibrosis","volume":"173","author":"Goss","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093013524326700_aaoag085-B5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1513\/AnnalsATS.201603-192BC","article-title":"Minorities are underrepresented in clinical trials of pharmaceutical agents for cystic fibrosis","volume":"13","author":"McGarry","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026093013524326700_aaoag085-B6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jcf.2023.05.008","article-title":"Center-level self-study identifies opportunities to advance equity in cystic fibrosis clinical trial participation","volume":"22","author":"Januska","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026093013524326700_aaoag085-B7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0022-3476(98)70441-x","article-title":"Comparison of the clinical manifestations of cystic fibrosis in black and white patients","volume":"132","author":"Hamosh","year":"1998","journal-title":"J Pediatr"},{"key":"2026093013524326700_aaoag085-B8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1378\/chest.14-2189","article-title":"Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with cystic fibrosis in California","volume":"149","author":"Buu","year":"2016","journal-title":"Chest"},{"key":"2026093013524326700_aaoag085-B9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1164\/rccm.201711-2357OC","article-title":"Disparities in mortality of Hispanic patients with cystic fibrosis in the United States. A national and regional cohort study","volume":"198","author":"Rho","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093013524326700_aaoag085-B10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ppul.21037","article-title":"Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population","volume":"44","author":"Watts","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"2026093013524326700_aaoag085-B11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026093013524326700_aaoag085-B12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.prrv.2021.12.001","article-title":"Left behind: the potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis","volume":"42","author":"McGarry","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"2026093013524326700_aaoag085-B13","author":"Milinic","year":"2025"},{"key":"2026093013524326700_aaoag085-B14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026093013524326700_aaoag085-B15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026093013524326700_aaoag085-B16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jcf.2020.05.010","article-title":"Changes in LCI in F508del\/F508del patients treated with lumacaftor\/ivacaftor: results from the prospect study","volume":"19","author":"Shaw","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026093013524326700_aaoag085-B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jcf.2022.07.008","article-title":"Characterizing CFTR modulated sweat chloride response across the CF population: initial results from the CHEC-SC study","volume":"22","author":"Mayer-Hamblett","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026093013524326700_aaoag085-B18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093013524326700_aaoag085-B19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2288-8-70","article-title":"Reducing bias through directed acyclic graphs","volume":"8","author":"Shrier","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"2026093013524326700_aaoag085-B20","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/ije\/dyw341","article-title":"Robust causal inference using directed acyclic graphs: the R package \u2018dagitty\u2019","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2026093013524326700_aaoag085-B21","author":"Symerio","year":"2020"},{"key":"2026093013524326700_aaoag085-B22","author":"GeoNames","year":"2006"},{"key":"2026093013524326700_aaoag085-B23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2026093013524326700_aaoag085-B24","doi-asserted-by":"publisher","first-page":"e65697","DOI":"10.7554\/eLife.65697","article-title":"Racial inequity in grant funding from the US National Institutes of Health","volume":"10","author":"Taffe","year":"2021","journal-title":"Elife."},{"key":"2026093013524326700_aaoag085-B25","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1158\/1078-0432.CCR-10-1451","article-title":"The impact of insurance on access to cancer clinical trials at a comprehensive cancer center","volume":"16","author":"Klamerus","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2026093013524326700_aaoag085-B26","volume-title":"Medical Apartheid: The Dark History of Medical Experimentation on Black Americans From Colonial Times to the Present","author":"Washington","year":"2006"},{"key":"2026093013524326700_aaoag085-B27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jcf.2024.03.013","article-title":"The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis","volume":"23","author":"Rosenfeld","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026093013524326700_aaoag085-B28","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s11524-016-0085-2","article-title":"Neighborhood socioeconomic status and primary health care: usual points of access and temporal trends in a major US urban area","volume":"93","author":"Hussein","year":"2016","journal-title":"J Urban Health"},{"key":"2026093013524326700_aaoag085-B29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1377\/hlthaff.2021.01805","article-title":"Race, place, and structural racism: a review of health and history in Washington, D.C","volume":"41","author":"King","year":"2022","journal-title":"Health Aff (Millwood)"},{"key":"2026093013524326700_aaoag085-B30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1001\/archinte.159.9.997","article-title":"Patient-physician racial concordance and the perceived quality and use of health care","volume":"159","author":"Saha","year":"1999","journal-title":"Arch Intern Med"},{"key":"2026093013524326700_aaoag085-B31","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41586-023-06382-0","article-title":"Consent document translation expense hinders inclusive clinical trial enrolment","volume":"620","author":"Velez","year":"2023","journal-title":"Nature"},{"key":"2026093013524326700_aaoag085-B32","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1200\/OP.20.01093","article-title":"Limited English proficiency and disparities in health care engagement among patients with breast cancer","volume":"17","author":"Roy","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2026093013524326700_aaoag085-B33","doi-asserted-by":"publisher","first-page":"101875","DOI":"10.1136\/ijgc-2024-005751","article-title":"Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel","volume":"35","author":"Pothuri","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"2026093013524326700_aaoag085-B34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/jgc4.1271","article-title":"The CFTR variant profile of Hispanic patients with cystic fibrosis: impact on access to effective screening, diagnosis, and personalized medicine","volume":"29","author":"Januska","year":"2020","journal-title":"J Genet Counsel"},{"key":"2026093013524326700_aaoag085-B35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol"},{"key":"2026093013524326700_aaoag085-B36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1475-9276-12-18","article-title":"Patient-centred access to health care: conceptualising access at the interface of health systems and populations","volume":"12","author":"Levesque","year":"2013","journal-title":"Int J Equity Health"},{"key":"2026093013524326700_aaoag085-B37","author":"US Food and Drug Administration","year":"2020"},{"key":"2026093013524326700_aaoag085-B38","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1186\/s12889-019-7683-3","article-title":"Aggregation of Asian-American subgroups masks meaningful differences in health and health risks among Asian ethnicities: an electronic health record based cohort study","volume":"19","author":"Gordon","year":"2019","journal-title":"BMC Public Health"},{"key":"2026093013524326700_aaoag085-B39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026093013524326700_aaoag085-B40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1513\/AnnalsATS.201808-564PS","article-title":"Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals","volume":"16","author":"Lederer","year":"2019","journal-title":"Ann Am Thorac Soc"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1093\/annalsats\/aaoag085\/68076143\/aaoag085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/10\/1446\/68076143\/aaoag085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/10\/1446\/68076143\/aaoag085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:52:49Z","timestamp":1790790769000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/23\/10\/1446\/8653580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,4,11]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/annalsats\/aaoag085","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,11]]}}}